Biogenera
Bologna, IT · 1 known investors
Biogenera develops DNA-based anti-gene oligonucleotide drugs using PNA (Ag-PNA) to silence altered genes that cause serious diseases, including aggressive pediatric tumors such as neuroblastoma via its BGA002 candidate targeting the MYCN gene. The pharmaceutical biotech company operates its patented MyGenera platform to identify precision-medicine gene therapies for cancers and rare diseases.
BiotechDeep TechHealthtech